CA
BIO icon

CoreCap Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

CoreCap Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47K Hold
5
– – ﹤0.01% 2617
2026
Q1 		$1.39K Hold
5
– – ﹤0.01% 2477
2025
Q4 		$1.51K Buy
+5
New +$1.56K ﹤0.01% 2528
2024
Q2 		– Sell
-122
Closed -$42.2K – 1712
2024
Q1 		$42.2K Buy
+122
New +$40.1K ﹤0.01% 1180
2022
Q3 		– Sell
-193
Closed -$96K – 697
2022
Q2 		$96K Buy
+193
New +$101K 0.01% 704

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

CoreCap Advisors's BIO Position: Q2 2026 in Review

CoreCap Advisors held its Bio-Rad Laboratories Class A (BIO) position steady in Q2 2026 at 5 shares worth $1.47K. The position accounts for ﹤0.01% of the portfolio, ranked #2617.

CoreCap Advisors first reported a position in BIO in Q2 2022 and has held it in 5 quarters since. The position peaked at $96K in Q2 2022. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • CoreCap Advisors held 5 shares of Bio-Rad Laboratories Class A worth $1.47K as of Q2 2026.
  • CoreCap Advisors left its Bio-Rad Laboratories Class A share count unchanged in Q2 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2617 holding.
  • CoreCap Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2022 and has held it in 5 quarters since.
  • CoreCap Advisors's Bio-Rad Laboratories Class A position peaked at $96K in Q2 2022.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.